Central retinal vein occlusion treated with Ozurdex: a case report and review of literature

J Ocul Pharmacol Ther. 2013 Feb;29(1):84-7. doi: 10.1089/jop.2012.0057. Epub 2012 Aug 1.

Abstract

Purpose: To describe the retinal changes occurring after Ozurdex(®) (Ozurdex, Allergan, Inc., Irvine, CA) injection and peripheral laser treatment in a case of central retinal vein occlusion (CRVO).

Case report: A 51-year-old Caucasian man with massive retinal edema (926 μm) and hand motion visual acuity due to severe CRVO was treated early with Ozurdex intravitreal injection. Detailed monthly follow-up examinations showed complete resorption of the edema (253 μm) after 2 months and a 20/32 visual outcome after 3 months. The patient subsequently developed peripheral retinal ischemia accompanied by recurrence of small retinal cystoid spaces (295 μm); therefore, he underwent an associated laser treatment on the involved peripheral retina, which led to a recovery in retinal thickness (280 μm). His visual acuity remained stable at 20/32.

Conclusions: Early Ozurdex injection in association with late laser photocoagulation was effective in the resorption of CRVO macular edema and in restoring reasonably good visual acuity.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Combined Modality Therapy
  • Dexamethasone / administration & dosage
  • Dexamethasone / therapeutic use*
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / therapeutic use*
  • Humans
  • Intravitreal Injections
  • Laser Coagulation / methods*
  • Macular Edema / etiology
  • Macular Edema / therapy
  • Male
  • Middle Aged
  • Retinal Vein Occlusion / pathology
  • Retinal Vein Occlusion / therapy*
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome
  • Visual Acuity / drug effects

Substances

  • Glucocorticoids
  • Dexamethasone